Spike S1 (B.1.1.7, Alpha Variant) (SARS-CoV-2) : ACE2 Inhibitor Screening Chemiluminescence Assay Kit

The Spike S1 (B.1.1.7 Variant) (SARS-CoV-2) : ACE2 Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of the interaction between the B.1.1.7 Variant of the SARS-CoV-2 Spike S1 protein and human ACE2 (angiotensin-converting enzyme 2) . This kit comes in a convenient 96-well format, with Biotinylated-ACE2 (amino acids 18-740), purified SARS-CoV-2 Spike S1 variant (del_HV69-70, del_Y144, N501Y, A570D, D614G, P681H) protein, Streptavidin-HRP, and assay buffers for 100 reactions. The SARS-CoV-2 Spike S1 (B.1.1.7 Variant) protein, included in the kit, provides a biologically relevant model for the investigation of SARS-CoV-2/ACE2 interaction.Figure 1. Assay Kit schematic.First, Spike S1 (B.1.1.7 Variant) is coated on a 96-well plate overnight. After washing and blocking, the protein is pre-incubated with an inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP. After a final wash, ELISA ECL substrate is added to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the efficacy of the binding of Spike S1 (B.1.1.7 Variant) to ACE2.Interested in having us perform the screening and profiling of inhibitors or blocking antibodies? Visit ourCoronavirus Service page.